Post-Myocardial Infarction and Hyperlipidemia – Updates to statins

22 Nov Post-Myocardial Infarction and Hyperlipidemia – Updates to statins

All TreatGx users now have access to the updated treatment algorithms for Post-Myocardial Infarction and Hyperlipidemia. As always, these updates include the TreatGx standard of providing personalized dosing based on pharmacogenetics, kidney function, liver function, and drug interactions.

In this update, all statin medications offered in our TreatGx software (atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin) have been reviewed to include detailed drug interaction dosing, as well as the latest guidance from the 2022 CPIC guidelines for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms [1].

References

1. Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clinical pharmacology and therapeutics. 2022;111(5):1007-1021.